Shared genetic contribution to ischemic stroke and Alzheimer's disease by Traylor, Matthew et al.
RESEARCH ARTICLE
Shared Genetic Contribution to Ischemic
Stroke and Alzheimer’s Disease
Matthew Traylor, PhD,1,2* Poneh Adib-Samii, MBBS,3* Denise Harold, PhD,4
the Alzheimer’s Disease Neuroimaging Initiative,
The International Stroke Genetics Consortium (ISGC), UK Young Lacunar Stroke
DNA resource, Martin Dichgans, MD,5,6 Julie Williams, PhD,7
Cathryn M. Lewis, PhD,2,8 Hugh S. Markus, DM,1
and the METASTROKE and International Genomics of
Alzheimer’s Project (IGAP) investigators
Objective: Increasing evidence suggests epidemiological and pathological links between Alzheimer’s disease (AD)
and ischemic stroke (IS). We investigated the evidence that shared genetic factors underpin the two diseases.
Methods: Using genome-wide association study (GWAS) data fromMETASTROKE1 (15,916 IS cases and 68,826 controls)
and the International Genomics of Alzheimer’s Project (IGAP; 17,008 AD cases and 37,154 controls), we evaluated known
associations with AD and IS. On the subset of data for which we could obtain compatible genotype-level data (4,610 IS
cases, 1,281 AD cases, and 14,320 controls), we estimated the genome-wide genetic correlation (rG) between AD and IS,
and the three subtypes (cardioembolic, small vessel, and large vessel), using genome-wide single-nucleotide polymorphism
(SNP) data. We then performed a meta-analysis and pathway analysis in the combined AD and small vessel stroke data sets
to identify the SNPs andmolecular pathways throughwhich disease riskmay be conferred.
Results: We found evidence of a shared genetic contribution between AD and small vessel stroke (rG [standard
error]5 0.37 [0.17]; p5 0.011). Conversely, there was no evidence to support shared genetic factors in AD and IS
overall or with the other stroke subtypes. Of the known GWAS associations with IS or AD, none reached significance
for association with the other trait (or stroke subtypes). A meta-analysis of AD IGAP and METASTROKE1 small vessel
stroke GWAS data highlighted a region (ATP5H/KCTD2/ICT1) associated with both diseases (p5 1.83 1028). A path-
way analysis identified four associated pathways involving cholesterol transport and immune response.
Interpretation: Our findings indicate shared genetic susceptibility to AD and small vessel stroke and highlight poten-
tial causal pathways and loci.
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Taken together, ischemic stroke (IS) and Alzheimer’sdisease (AD) place an enormous burden on global
health care. Both are among the leading causes of
acquired disability worldwide,1,2 and the lifetime risk of
AD or stroke is as high as 1 in 2 for women and 1 in 3
for men.3 An estimated 24.3 million people were
thought to have dementia in 2001, and this is expected
to rise to 81.1 million by 2040.2,4
Increasing evidence suggests epidemiological and
pathological links between AD and IS. Population-based
studies have shown AD to be a risk factor for developing
IS,5,6 and vice versa,7 suggesting that shared pathological
processes may be involved in both conditions. Other
studies have indicated a synergistic relationship between
cerebral infarction and AD, with the combination of
both leading to an increased risk of cognitive decline and
dementia. Studies have also shown that cerebrovascular
events lead to more-rapid cognitive decline in patients
with AD.8 Postmortem studies have shown that individu-
als with cerebral infarcts as well as neuropathological AD
had a markedly increased risk of dementia in life com-
pared with those with AD pathology without
infarcts.9–11
The predominant vascular lesion in AD is cerebral
amyloid angiopathy (CAA),12,13 and although CAA is
more prevalent in IS than controls, it is not a common
cause of IS.14 The predominant cerebral vascular pathol-
ogies in IS are large vessel atherosclerosis (large vessel dis-
ease; LVD)15,16 and small vessel arteriosclerosis (small
vessel disease; SVD).17 Both pathologies have been asso-
ciated with AD. In particular, at least one third of AD
cases have pathological evidence of moderate or severe
SVD.18 AD and vascular pathologies are, however, tem-
porally and anatomically distinct. This has led to the
hypothesis that cerebrovascular disease may make the
brain more susceptible to AD pathology, potentially by
impairing clearance of amyloid.19 Alternatively, AD and
IS may represent independent, but convergent, diseases
that share some pathophysiological processes and there-
fore may be expected to share genetic risk factors.
Genome-wide association studies (GWAS) have
recently begun to identify the common genetic compo-
nent of many diseases such as AD and IS. More than 20
variants have now been identified that contribute to
AD,20–22 and in IS recent progress has resulted in the
identification of a number of variants, the majority of
which have been associated with specific stroke sub-
types.23–28 Indeed, recent evidence from GWAS indicates
that a large proportion of risk in complex diseases such
as AD and IS is attributable to the combined effects of a
large number of common genetic variants,29,30 each
conferring only a small amount of disease risk.31–33
Recent studies estimate the proportion of variance
explained by the genetic contribution from common var-
iants to AD and IS to be approximately 24.0% and
18.0%, respectively. 29,34
Genomic-relatedness-matrix restricted maximum
likelihood (GREML) methods have been one of the key
methodological advances that, in recent years, have
improved understanding of the common genetic influ-
ence on and between complex traits. These approaches
use distant relatedness between individuals to infer herit-
ability and coheritability of complex traits and have been
used to provide insights into and between many dis-
eases.35–37 We performed a bivariate GREML analysis in
two large GWAS cohorts consisting of AD and IS cases
and controls to assess evidence of a shared genetic contri-
bution to the two diseases. We initially sought to deter-
mine whether there was evidence of a shared genetic
contribution to IS and AD and then sought to determine
whether this association was particular to a specific sub-
type of IS. Finally, through a meta-analysis and subse-
quent pathway analysis of the two data sets, we sought to
identify the molecular pathways through which shared
disease risk may be conferred.
Participants and Methods
Study Design and Participating Cohorts
Two different sets of cases and controls were used in two
different parts of the analysis (Table 1). For the meta-
analysis and subsequent pathway analysis (analyses i, iii,
and iv), we used data from METASTROKE1 and the
International Genomics of Alzheimer’s Project (IGAP) as
follows.
The METASTROKE1 data set consisted of IS
cases and controls derived from three previously pub-
lished populations: METASTROKE,38 WTCCC2-
Immunochip,39 and UK Young Lacunar Stroke DNA
resource.40 All cohorts consisted of IS cases of European
ancestry from Europe, North America, and Australia
together with controls of matched ancestry. Where possi-
ble, stroke cases were subtyped according to the Trial of
Org 10172 in Acute Stroke Treatment (TOAST) classifi-
cation system.41 Information on clinical subtypes was
available for 60.1% of cases. In two centers, the Heart
Protection study (N cases/controls5 578/468) and Rot-
terdam (N cases/controls5 376/5396), TOAST subtyp-
ing was not performed. All populations were genotyped
on standard platforms from Affymetrix (Affymetrix, San
Diego, CA) or Illumina (Illumina, San Diego, CA) and
imputed separately to reference data sets. The results of
the association analyses from each group (META-
STROKE, WTCCC2-Immunochip, and DNA-lacunar)
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were meta-analyzed using a fixed-effects inverse-variance
weighted model using METAL.42 Single-nucleotide poly-
morphisms (SNPs) available in a sufficient number of
stroke cases (>1,000) were included in the meta-analysis.
The IGAP is a large, two-stage study based upon
GWAS on individuals of European ancestry. In stage 1,
the IGAP used genotyped and imputed data on
7,055,881 SNPs to meta-analyze four previously pub-
lished GWAS data sets consisting of 17,008 AD cases
and 37,154 controls (the European Alzheimer’s disease
Initiative [EADI], the Alzheimer Disease Genetics Con-
sortium [ADGC], the Cohorts for Heart and Aging
Research in Genomic Epidemiology consortium
[CHARGE], and the Genetic and Environmental Risk in
AD consortium [GERAD]). In stage 2, 11,632 SNPs
were genotyped and tested for association in an inde-
pendent set of 8,572 AD cases and 11,312 controls.
Finally, a meta-analysis was performed combining results
from stages 1 and 2. In this analysis, only results from
stage 1 were used. All AD cases met criteria for either
possible, probable (NINCDS-ADRDA, DSM-IV), or
definite (CERAD) AD.
For the bivariate GREML analyses (analysis ii), we
obtained genotype level data consisting of AD cases and
controls from LOAD-CIDR,43 the Alzheimer’s Disease
Neuroimaging Initiative (ADNI), and eMERGE (Group
Health) 44; IS cases and controls from the WTCCC2
ischemic stroke study,23 the Australian Stroke Genetic
Collaborative, and Besta Stroke Register (Milano)38 and
independent controls from RADIANT,45 People of the
British Isles (POBI),46 and the Health ABC studies.47 All
were genotyped on the Illumina 610k, 660k, 1M, or
1.2M arrays. We performed quality control independ-
ently on each data set, at the minimum removing SNPs
genotyped in less than 97% of individuals, SNPs diverg-
ing from Hardy-Weinberg equilibrium (p<1e-6), and
SNPs with minor allele frequency <1%. We then merged
all individuals together and included only SNPs present
in >99.9% of individuals, again removing SNPs diverg-
ing from Hardy-Weinberg equilibrium (p<1e-6). We
performed ancestry-informative principal components
analysis with smartpca (EIGENSTRAT), 48 removing
any individuals more than 6 standard deviations from
the mean on any of the first five principal components
over five iterations. The remaining individuals were used
to calculate the first 30 principal components.
Statistical Analyses
ANALYSIS OF GWAS SIGNIFICANT LOCI. We first
determined whether any of the loci considered significant
in large meta-analyses of IS and AD were significantly
associated with risk of the other disease. In selecting IS
associated SNPs, we considered the five loci (9p21,
HDAC9, PITX2, ZFHX3, and 12q24.12) associated with
stroke in METASTROKE and in a recent publica-
tion.38,39 We set a p-value threshold of p5 0.01 to deter-
mine significance, using the Bonferroni method to
correct for five independent tests. In selecting AD-
associated SNPs, we considered all independent loci asso-
ciated with AD in the largest meta-analysis to date, as
well as any other loci which have been identified since
that publication.22,49,50 We identified 22 such associa-
tions and set the corresponding Bonferroni-corrected p-
value threshold at p5 0.0023. Where SNPs were not
available in METASTROKE (six SNPs), we evaluated
the available SNP that most strongly tagged the associ-
ated SNP.
GENETIC CORRELATION ANALYSIS. To estimate the
genetic correlation between AD and IS, we performed a
bivariate GREML analysis using the GCTA package (ver-
sion 1.24.2).51,52 The approach involves estimating the
distant relatedness between all individuals based on com-
mon SNPs represented on GWAS arrays. Linear mixed
models are then used to estimate the proportion of
(co)heritability explained by the relatedness between
TABLE 1. Data Description
Summary-Level Analysis GREML Analysis
Cases Controls Cases Controls
Alzheimer’s disease 17,008 37,154 1,281 14,320
All ischemic stroke 15,916 68,826 4,610
Cardioembolic stroke 3,127 60,861 1,013
Large vessel stroke 2,876 54,866 1,231
Small vessel stroke 3,651 58,657 851
GREML5 genomic-relatedness-matrix restricted maximum likelihood.
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individuals. We present our results as the estimated
genetic correlation between the two diseases, rG, which
is a value between –1 and 1 that can be interpreted as
the degree of genetic effects shared by the two traits.
Intuitively, rG would be positive when AD-IS pairs are
more related than IS-control and AD-control pairs and
negative when AD-IS pairs are less related then IS-
control and AD-control pairs. We tested whether the cor-
relation was significantly different from zero (rG 6¼0),
interpreting a significant test for rG6¼0 as evidence that
genetic liability was shared between the two traits. In our
analysis, we included the first 10 principal components
in each analysis and removed distantly related individuals
above a suggested threshold (>0.025). Estimates can be
upwardly biased if related individuals remain in the sam-
ple32; this threshold is included to avoid this problem
from arising. In addition, we evaluated the sensitivity of
the results by repeating the analysis using a stricter minor
allele frequency threshold (0.05), genotyping missingness
threshold (99.95%), relatedness threshold (0.02), and a
greater number of principal components (20) in the
model. In all analyses, only autosomal SNPs were
included.
META-ANALYSIS OF AD WITH SMALL VESSEL STRO-
KE. The results of the 17,008 AD cases and 37,154 con-
trols from IGAP and the 3,652 SVD cases and 58,657
controls from METASTROKE1were meta-analyzed
using Stouffer’s method, as implemented in METAL.42
Because our aim was to identify the genetic variants con-
tributing to both disorders, we attributed equal weights to
each of the diseases. After meta-analysis, we extracted only
those SNPs with no evidence of heterogeneity between the
two data sets (p> 0.01), thereby removing SNPs that were
associated with only one of the two traits. The remaining
SNPs were then taken forward for further investigation,
and all others were discarded. We used the Zaykin method
to correct for inflation attributable to shared controls.53
IDENTIFICATION OF SHARED DISEASE PATH-
WAYS. We then determined whether the meta-analyzed
results showed significant enrichment for annotated path-
ways and gene sets from the Gene Ontology (GO), BIO-
CARTA, REACTOME, and Kyoto Encyclopedia of
Genes and Genomes (KEGG) libraries. We used the
gene set enrichment analysis (GSEA) approach, as imple-
mented in the MAGENTA software package,54 to deter-
mine the enrichment within the 1,488 gene sets that had
more than 15 and less than 200 genes in our data set. A
p value of significance for each gene set was then calcu-
lated, along with a false discovery rate (FDR) q value,
estimated using the Benjamini-Hochberg procedure.55
We used an FDR threshold of 0.05 to identify associated
gene sets. We used a second pathway analysis approach
(GSEA-VEGAS) to verify any associated sets as follows.
We calculated gene-level association statistics for all genes
using VEGAS56 and then calculated a gene-set enrich-
ment statistic for each of the pathways. We calculated an
empirical p value by sampling random gene sets with the
same number of genes as the tested pathway and com-
pared GSEA-enrichment statistics between the simulated
and tested pathways.
ADNI. Data used in the bivariate GREML analyses were
obtained from the ADNI database (adni.loni.usc.edu). The
ADNI was launched in 2003 as a public-private partner-
ship, led by Principal Investigator Michael W. Weiner,
MD. The primary goal of ADNI has been to test whether
serial magnetic resonance imaging, positron emission
tomography, other biological markers, and clinical and
neuropsychological assessment can be combined to measure
the progression of mild cognitive impairment and early
AD. For up-to-date information, see www.adni-info.org.
Results
Analysis of GWAS Significant Loci
None of the SNPs associated with IS were associated
with AD (p> 0.1). Similarly, none of the SNPs associ-
ated with AD passed Bonferroni correction for associa-
tion with IS or any of the three subtypes. The strongest
association was with rs11870474 [ATP5H/KCTD2] for
small vessel stroke (p5 0.0042; Supplementary Table 1).
Indeed, the odds ratio (OR) for association of this SNP
FIGURE 1: Genetic correlation between ischemic stroke (and
ischemic stroke subtypes) and Alzheimer’s disease showing
estimate and 95% CI. CE5 cardioembolic; CI5 confidence
interval; IS5 ischemic stroke; LVD5 large vessel disease;
rG5genome-wide genetic correlation; SVD5 small vessel
disease. [Color figure can be viewed in the online issue,
which is available at www.annalsofneurology.org.]
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with small vessel stroke was larger than for association
with AD (SVD, 1.26 [1.08–1.48]; AD, 1.18 [1.08–
1.30]). In addition, 17 of 22 SNPs had a concordant
allelic effect direction between SVD and AD (two-sided,
p5 0.017), suggesting that although these individual
SNPs did not show statistical evidence of association
with SVD, the set may be enriched for SNPs with true,
but small, effects on SVD. Conversely, no excess in shar-
ing of direction of effect was identified for all IS, or for
the cardioembolic (CE) or LVD subtypes.
GENETIC CORRELATION ANALYSIS. A total of
278,233 SNPs and 22,208 individuals were used to con-
struct the genetic relationship matrix used in the analysis.
Univariate estimates of AD and IS heritability were in
line with previous published estimates. There was a sig-
nificant correlation between the genetic contribution
underpinning SVD and AD (rG [standard error;
SE]5 0.37 [0.17]; p5 0.011; Fig 1). Conversely, there
was no evidence to support shared genetic factors under-
pinning AD and all IS (rG [SE]5 0.06 [0.08]; p5 0.24)
or any of the other stroke subtypes: CE (rG [SE]5 0.08
[0.12]; p5 0.25) and LVD (rG [SE]5 0.00 [0.11];
p5 0.49). The association between SVD and AD was
not affected by changes in minor allele frequency thresh-
old (0.05), genotyping missingness threshold (99.95%),
relatedness threshold (0.02), and number of principal
components (20) in the model; all estimates of rG were
between 0.35 and 0.37, and p values for rG>0 were
all 0.026.
META-ANALYSIS OF AD WITH SMALL VESSEL STRO-
KE. Having established that susceptibility to AD
appears to be shared only with SVD, we performed a
meta-analysis of currently available GWAS data in SVD
(METASTROKE1) and AD (IGAP). One region, near
to ATP5H/KCTD2, was associated with AD and SVD at
genome-wide significance (p5 1.83 1028; Fig 2). Var-
iants in this region have been associated at genome-wide
significance with AD in a recent study,49 and this is the
same region, albeit a different SNP in partial LD
(r250.60), that produced the strongest association in sec-
tion i above. This particular SNP, rs9899728, showed a
larger effect on SVD (OR [95% confidence interval
{CI}]5 1.32 (1.14–1.52); p5 0.00014) than AD (OR
[95% CI]5 1.20 [1.11–1.30]; p5 7.13 1026) and falls
FIGURE 2: Association of ATP5H/KCTD2 locus with AD and SVD by genomic position and forest plot showing effect of risk
SNP on SVD and AD with 95% CIs. AD5Alzheimer’s disease; CI5 confidence interval; SNP5 single-nucleotide polymorphism;
SVD5 small vessel disease. [Color figure can be viewed in the online issue, which is available at www.annalsofneurology.org.]
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between two genes: Immature Colon Carcinoma Tran-
script 1 (ICT1) and adenosine triphosphate (ATP) syn-
thase, H1 transporting, mitochondrial Fo complex,
subunit (ATP5H).
IDENTIFICATION OF DISEASE PATHWAYS SHARED
BETWEEN AD AND SVD. The MAGENTA pathway
analysis identified four significant pathways using the sig-
nificance criteria of FDR q value< 0.05 (Table 2). Three
of these involve lipid transport (GO/phospholipid efflux,
GO/cholesterol efflux, and GO/reverse cholesterol trans-
port), whereas one involves immune response (GO/nega-
tive regulation of nuclear factor kappa B [NF-jB]
transcription factor activity). When validating each signif-
icant pathway using an alternative method (GSEA-
VEGAS), all pathways were associated at p 0.011,
whereas three were associated at p 0.0015.
Discussion
Our results support the hypothesis that shared pathophysio-
logical processes underlie both IS and AD, but suggest that
this shared association is only with SVD and not with the
other stroke subtypes. When investigating the genetic corre-
lation between AD and IS, we found evidence that the cumu-
lative effect of SNPs each individually conferring less risk,
and therefore not reaching GWAS significance for stroke, are
shared between AD and SVD, with no evidence to support
association with any other stroke subtype.
Having established that AD and SVD share a sub-
stantial proportion of genetic susceptibility, we then sought
to identify the genetic variants and shared molecular path-
ways through which AD and SVD disease risk is conferred.
Our meta-analysis highlighted one particular region on
chromosome 17 in a region encompassing three
genes; ICT1/KCTD2/ATP5H, which has previously been
implicated in AD.49 In addition, we found evidence of
association with four pathways. Three of these involve lipid
transport, whereas the other involves immune response.
In addition, we used data from large GWASs in IS
and AD to determine whether GWAS significant loci
previously identified in AD are associated with stroke
and whether known stroke loci associated with AD. We
could find no significant associations, indicating that the
contribution of specific associations identified thus far do
not contribute a considerable proportion of genetic risk
to the reciprocal disease.
The relationship between AD and IS is not fully
understood. Vascular risk factors have been associated
with AD,57 and a variety of cerebrovascular pathologies
including IS have been reported to be more frequent in
AD cases than controls.15–17 However, whether IS and
AD pathologies are merely additive, or whether IS
pathology directly promotes the development and pro-
gression of AD pathology, is debated.57 Possible mecha-
nisms for the latter include cerebral hypoperfusion
induced by cerebrovascular disease initiating or accelerat-
ing the neurodegeneration cascade, causing amyloid dep-
osition and synaptic and neuronal dysfunction.57 In
addition, whether there are shared pathological processes
contributing to both IS and AD is uncertain. Our results
offer new insights into this relationship. Previous studies
have found that lacunar stroke, the hallmark of SVD, is
associated with worse cognition in patients with AD
pathology,10 although the relationship is still debated.57
A number of studies have reported that large artery ath-
erosclerosis, in the carotid and intracranial arteries, is
associated with AD risk.15,16,58 Our results do not sup-
port this and instead suggest that the most important
cerebrovascular pathology mediating the relationship
between IS and AD is SVD.
TABLE 2. Significant Pathways Associated With SVD and AD From MAGENTA Analysis
MAGENTA Analysis
GSEA-VEGAS
Validation
Gene set No. of Genes
in Set
p FDR q Value p
GO/phospholipid efflux 10 1.13 1025 4.03 1024 0.0015
GO/cholesterol efflux 20 1.03 1024 1.23 1022 0.0017
GO/reverse cholesterol transport 16 3.03 1024 3.33 1022 0.0018
GO/negative regulation of
NF-jB transcription factor activity
15 2.03 1024 3.53 1022 0.011
AD5Alzheimer’s disease; FDR5 false discovery rate; GO5 gene ontology; GSEA5 gene-set enrichment analysis; NF-
jB5 nuclear factor kappa B; SVD5 small vessel disease; VEGAS5 versatile gene-based association statistic method.
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Our study has limitations. Cases from both IGAP
and METASTROKE1 are drawn from a number of
international centers. We therefore cannot rule out the
effect of differences in screening techniques and other
diagnostic biases on our study. The relationship between
IS and AD could be mediated, at least in part, by shared
cardiovascular risk factors. We did not have risk factor
data on all cases and controls to allow this to be adjusted
for. However, if the association was driven by risk factors,
we might expect this to affect all subtypes of stroke and
would therefore not explain why our association is spe-
cific to small vessel stroke. When evaluating the APOE
e4 allele, we used SNPs from HapMap II populations
which are in partial linkage disequilibrium with the true
variant. Without genotyping the causal allele, we cannot
completely rule out an association, although if a strong
association existed, we would expect it to be identified in
our analysis. The diagnosis of AD was made using either
established clinical criteria or pathophysiological confir-
mation; however, pathological studies having shown coex-
istent vascular pathology are not uncommon, and this
could account for part of the shared risk. One other con-
cern in analyses such as this, which include a large num-
ber of variables and individuals, is that subtle biases can
influence the results. We took great care to only include
samples that were genotyped on similar arrays from Illu-
mina and directly assessed relatedness between individu-
als based on genotypes. In addition, our results were not
sensitive to changes in parameters used, such as minor
allele and relatedness thresholds.
In summary, our results demonstrate that a propor-
tion of the common genetic susceptibility to AD is
shared with SVD, but not with any other stroke sub-
types. Our results provide a baseline for further study
into the complex relationship between AD and SVD
through genome-wide analyses.
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